Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
Public ClinicalTrials.gov record NCT04365101. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/II Study of Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (CYNK-001) for the Treatment of Adults With COVID-19
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is a Phase 1 / 2 trial to determine the safety and efficacy of CYNK-001, an immunotherapy containing Natural Killer (NK) cells derived from human placental CD34+ cells and culture-expanded, in patients with moderate COVID-19 disease.
Study identification
- NCT ID
- NCT04365101
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 7 participants
Conditions and interventions
Conditions
- Coronavirus
- Coronavirus Infection
- Severe Acute Respiratory Syndrome Coronavirus 2
- Pneumonia
- Pneumonia, Viral
- Lung Diseases
- Respiratory Tract Disease
- Respiratory Tract Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Disease
- Immunologic Disease
- ARDS
- Immunologic Factors
- Physiological Effects of Drugs
- Antiviral Agents
- Anti-infective Agents
- Analgesics
- Antimetabolites, Antineoplastic
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 1, 2020
- Primary completion
- Aug 29, 2021
- Completion
- Feb 14, 2023
- Last update posted
- Jun 25, 2026
2020 – 2023
United States locations
- U.S. sites
- 4
- U.S. states
- 3
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UC Irvine | Irvine | California | 92697 | — |
| Atlantic Health | Morristown | New Jersey | 07960 | — |
| Atlantic Health | Summit | New Jersey | 07901 | — |
| Multicare Health System | Tacoma | Washington | 98405 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04365101, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 25, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04365101 live on ClinicalTrials.gov.